Pharmacokinetics and Effects on Fibrinolytic and Coagulation Parameters of Two Doses of Recombinant Tissue-Type Plasminogen Activator in Healthy Volunteers

M Verstraete; C A P F Su; P Tanswell; W Feuerer; D Collen

doi:10.1055/s-0038-1661592

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1986; 56(01): 001-005
DOI: 10.1055/s-0038-1661592

Original Article

Schattauer GmbH Stuttgart

Pharmacokinetics and Effects on Fibrinolytic and Coagulation Parameters of Two Doses of Recombinant Tissue-Type Plasminogen Activator in Healthy Volunteers

M Verstraete

^*The Center for Thrombosis and Vascular Research, Campus Gasthuisberg, University of Leuven, Leuven, Belgium

,

C A P F Su

^**The Departments of Clinical Pharmacology and Biochemistry, Dr. Karl Thomae GmbH, Biberach an der Riss, West Germany

,

P Tanswell

^**The Departments of Clinical Pharmacology and Biochemistry, Dr. Karl Thomae GmbH, Biberach an der Riss, West Germany

,

W Feuerer

^**The Departments of Clinical Pharmacology and Biochemistry, Dr. Karl Thomae GmbH, Biberach an der Riss, West Germany

,

D Collen

^*The Center for Thrombosis and Vascular Research, Campus Gasthuisberg, University of Leuven, Leuven, Belgium

› Institutsangaben

Abstract

als PDF herunterladen

Summary

Pharmacokinetics and pharmacological effects of two intravenous doses of recombinant tissue-type plasminogen activator (rt-PA) (40 and 60 mg over 90 min) were determined in healthy volunteers. Mean maximum plasma concentrations were 1080 and 1560 ng/ml respectively. The steady state level during subsequent maintenance infusion of 30 mg over 6 h was 250 ng/ml. The pharmacokinetics of rt-PA showed a bi-exponential disappearance from plasma consistent with a 2-compartment model of t_½α = 5.7 min, a t_½β = 1.3 h and a total clearance of 380 ml/min.

Mean fibrinogen levels at the end of the infusions of 40 mg or 60 mg rt-PA over 90 min, measured in thawed plasma samples collected on citrate/aprotinin, decreased to 74% and 57% of the preinfusion values respectively. Plasminogen fell to 55% and 48%, and α₂-antiplasmin to 28% and 18% of initial values. No further decrease of these parameters was observed during the infusion of 30 mg rt-PA over 6 h. Only 2% of the preinfusion fibrinogen levels could be recovered as fibrinogen-fibrin degradation products. This moderate extent of systemic fibrinogenolysis is much less than that reported for therapeutic i.v. infusions of streptokinase.

Keywords

Fibrinolysis - Tissue-type plasminogen activator - Fibrinogen - Plasminogen - Pharmacokinetics

PDF (989 kb)

Referenzen

References
1 Collen D. Human tissue-type plasminogen activator: from the laboratory to the bedside. Editorial. Circulation 1985; 72: 18-20
2 Collen D, Lijnen HR. New approaches to thrombolytic therapy. Arteriosclerosis 1984; 4: 579-584
3 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl M, Schmidt W, Uebis R, von Essen R. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 1: 842-847
4 Verstraete M, Bleifeld W, Brower RW, Charbonnier B, Collen D, de Bono DP, Dunning AJ, Lennane RJ, Lubsen J, Mathey DG, Michel PL, Raynaud PH, Schofer J, Vahanian A, Vanhaecke J, van de Kley GA, van de Werf F, von Essen R. Double-blind, randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985; 2: 965-969
5 Verstraete M, Bounameaux H, de Cock F, van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985; 235: 506-512
6 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda T, Bulkley BH, Robison AK, Huter AM, Bell WR, Spadaro JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective randomized placebocontrolled trial. Circulation 1984; 70: 1012-1017
7 Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns J, Grossbard EB, Palacios I, Collen D. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation (in press)
8 Friberger P, Knos P. Plasminogen determination in human plasma. In: Chromogenic Peptide Substrates Scully MS, Kakkar VV. (eds.) pp 128 Churchill Livingstone; Edinburgh: 1979
9 Eddy J, de Cock F, Collen D. Inhibition of plasmin by normal and antiplasmin-depleted human plasma. Thromb Res 1976; 8: 513-518
10 Merskey C, Lalezari P, Johnson AJ. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med 1969; 131: 871-875
11 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-246
12 Vermylen C, de Vreker R, Verstraete M. A rapid method for assay of fibrinogen-fibrin polymerization time. Clin Chim Acta 1963; 8: 418-424
13 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enyzme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
14 Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
15 Heinzei G. In: Pharmacokinetics during drug development Bozler G, van Rossum SM. (eds.) p 207 Fischer; Stuttgart - New York: 1982
16 Gibaldi M, Perrier G. Pharmacokinetics. Ch. 2. Marcel Dekker; New York: 1982
17 Von Hattingberg HM, Brockmeier D. In: Pharmacokinetics during drug development. Bozler G, van Rossum SM. (eds.) pp 315-323 Fischer; Stuttgart - New York: 1982
18 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
19 Tiefenbrunn AJ, Robison AK, Kurnik PB, Ludbrook PA, Sobel BE. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1985; 71: 110-116
20 Holvoet P, Lijnen HR, Collen D. Monoclonal antibodies directed against the fibrin-binding site or the active site of human tissue-type plasminogen activator (t-PA). Thromb Haemostas 1985; 54: 108 (Abstr)
21 Collen D, Bounameaux H, de Cock F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator (rt-PA) in patients with acute myocardial infarction. Circulation (in press)
22 Timmis GC, Gangadharan V, Ramos RC, Hauser A, Westveer DC, Stewart G, Goodfliesh R, Gordon S. Hemorrhage and the products of digestion after intracoronary administration of streptokinase. Circulation 1984; 69: 1146-1152
23 Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 1974; 2: 123-148
24 Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165-175